Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Cancer Res. 2019 Mar 15;79(9):2195–2207. doi: 10.1158/0008-5472.CAN-18-2133

Figure 4: Gefitinib induces CRC repression through activation of IP3R3.

Figure 4:

A-B) HT-29 cells transduced with either scrambled or IP3R3 shRNAs, then treated with vehicle or 10 μM gefitinib/1 μM MI-2–2. Cell growth was assessed after 96 hours by the MTS assay (A) and protein levels were assessed after 48 hours by western blot (B). C) Quantitation and normalization of cleaved and uncleaved PARP levels on western blot from Figure 4B. D) HT-29 cells treated with vehicle or 10 μM gefitinib/1 μM MI-2–2 with different concentrations of caffeine for 96 hours with cell growth assessed by the MTS assay. E-F) HT-29-GCaMP6f cells treated for 24 hours with cytosolic calcium levels analyzed by flow cytometry (E), with the median FLH-1 values reported (F). 10 μM gefitinib, 2 mM caffeine. *p < 0.05.